This atlas provides valuable guidance for medical students, residents, fellows, nurses, attending physicians, and other allied health professionals taking care of patients with graft-versus-host disease (GVHD). Our understanding about the intricacies of GVHD diagnosis and treatment are constantly developing as basic and translational science in the field evolves. As such, this text reflects the best current evidence we have to date for clinicians treating patients with GVHD.
The Atlas of Graft-versus-Host Disease is a concise and useful graphical resource providing comprehensive guidance required for a disease entity that has a heterogeneous and complicated clinical presentation. It has been written with input of both oncologists and dermatologists, which has enabled the capture of perspectives and nuances of GVHD diagnosis and management that can influence readers with varied training backgrounds and current clinical practice, thus creating a powerful and useful resource for readers.
About the Author
Dr Cotliar joined the David Geffen School of Medicine at UCLA faculty in 2004 after training there in both internal medicine and dermatology. While at UCLA, he directed the dermatology inpatient consult service and was heavily involved in the care of bone marrow transplant recipients. In 2010, he joined the faculty at the Northwestern University Feinberg School of Medicine Department of Dermatology. While there, he was the Director of the Combined Dermatology-Medicine Training Program, as well as the Director of Clinical Operations within the Dermatology department. He was also Director of Photopheresis for Northwestern Memorial Hospital, and led the TARGET (Treatment of Adverse Reactions and GVHD EffecTs of Cancer) program. While at Northwestern, he received a medical dermatology career development award from the Dermatology Foundation to study “Improvement in the diagnosis of acute graft-versus-host disease.”
Dr Cotliar’s clinical and research focus is GVHD and toxicities related to anticancer therapies (both traditional chemotherapeutics and targeted agents). He has given many talks at national and international dermatology meetings, and has presented posters at ASCO, American Academy of Dermatology Annual Meeting, Society of Investigational Dermatology Annual Meeting, American Society of Bone Marrow Transplantation Annual Meeting, and World Congress of Dermatology. In 2015, he was recruited to join City of Hope Comprehensive Cancer Center to lead a new Division of Dermatology.